ACAD — Acadia Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $4.34bn
- $3.48bn
- $1.07bn
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP
Acadia Pharmaceuticals Q1 revenue rises on DAYBUE growth
Brief: Acadia Pharmaceuticals Q1 EPS USD 0.02
U.S. RESEARCH ROUNDUP-Crowdstrike, Oracle, Vulcan Materials
Brief: Acadia Pharmaceuticals Appoints Jonathan M. Poole To Its Board Of Directors
Brief: EMA's CHMP Recommended Granting A Marketing Authorisation For Mcombriax
Acadia Pharmaceuticals Q4 revenue rises 9% yr/yr
Brief: Acadia Pharmaceuticals Q4 EPS USD 1.6
Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts
Jefferies cuts PT, earnings forecasts on Australia's Neuren after setback for Rett drug in Europe
U.S. RESEARCH ROUNDUP-Adobe, Exxon Mobil, Stellar Bancorp
Acadia Pharma down after negative EU trend vote on neurological disorder drug
Brief: Acadia Pharmaceuticals Provides Update On Regulatory Submission For Trofinetide For The Treatment Of Rett Syndrome In The European Union
Brief: Acadia Pharmaceuticals Provides Business And Pipeline Updates At 44Th Annual J.P. Morgan Healthcare Conference
Australia's Neuren soars as partner Acadia wins FDA nod for Rett syndrome treatment
Brief: Acadia Pharmaceuticals Announces FDA Approval Of DAYBUE STIX For Oral Solution, A New Powder Formulation Of Trofinetide For The Treatment Of Rett Syndrome